Dengue Fever News and Research

RSS

Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms typically begin three to fourteen days after infection. These may include a high fever, headache, vomiting, muscle and joint pains, and a characteristic skin rash.

Times of India examines dengue vaccine trials

India could soon become a site for clinical trials to evaluate the effectiveness of a dengue vaccine, the Times of India reports. According to the drug controller general of India, vaccine maker Sanofi Pasteur recently submitted a proposal to test the vaccine to the country.

11 Feb 2011

Global Health Consortium to support development of vaccines to control dengue fever

The International Vaccine Institute today announced the launch of the Dengue Vaccine Initiative, in collaboration with the Sabin Vaccine Institute, the Johns Hopkins University, and the World Health Organization, to support development of vaccines to control dengue fever, a widespread and expanding hemorrhagic fever that is endemic in most tropical and subtropical regions of the world.

10 Feb 2011

New study shows economic burden of dengue in Western Hemisphere is $2.1 billion per year

Dengue illness, the most common mosquito-borne viral disease in the world, has expanded from its Southeast Asian origins and is resurgent in countries such as Argentina, Chile and the continental United States.

8 Feb 2011

Study finds total cost of dengue illness in Americans to be $2.1 billion per annum

The first assessment of the total cost of dengue illness in the Americas reveals the economic burden to be approximately $2.1 billion per year, exceeding that from other viral illnesses including human papillomavirus and rotavirus.

4 Feb 2011

Surge of mosquito borne disease in South Australia following wet weather

Rising water in the Murray River has caused a surge in mosquito-borne infections in South Australia. The water is rising in the Murray in SA as floodwaters move downstream from the eastern states.

2 Feb 2011

Inviragen completes memorandum of understanding with Duke-NUS

Inviragen, and the Duke-National University of Singapore Graduate Medical School announced today that they have completed a memorandum of understanding to establish a partnership between the two organizations.

27 Jan 2011

Dr. Kathleen receives NSF grant to measure how climate change will impact risk of malaria, dengue fever

Thanks to a $250,000 National Science Foundation grant we may soon know how climate change will impact our risk of malaria and dengue fever. Dr. Kathleen Schreiber, professor of geography at Millersville University of Pennsylvania, received the grant from the NSF sponsored Vector-Borne Disease Project to measure how environmental temperature change influences the transmission and disease risk of the two diseases.

19 Jan 2011

Washington Post examines theories on climate change's potential impact on disease spread

The Washington Post examines the debate among scientists over the impact climate change might have on the spread of infectious diseases, and the potential for a rise in the number of tropical diseases in the U.S. The article describes how extreme weather conditions, such as flooding and drought - "thought to be linked to the warming of the oceans and to changes in the precipitation cycle" - can create ideal conditions for waterborne disease.

13 Jan 2011

Floods may become a healthcare challenge, warns the AMA

The Australian Medical Association (AMA) has issued warnings to the Queensland health authorities to prepare for the rise of illnesses and injuries caused by the floods.

10 Jan 2011

Trial to eliminate deadly Dengue begins

The 12 week programme costing $18 million named ‘Eliminate Dengue’ has commenced. Mosquitoes bearing a special bacteria would be released into the wild around Cairns as part of a trial to rid the area of the insects that carry Dengue fever.

4 Jan 2011

EPA to clean up vector-breeding site to eliminate dengue epidemic

To control the severe dengue epidemic, the Environmental Protection Administration (EPA) said the first priority is to locate diagnosed patients and eliminate virus-carrying mosquitoes, the vectors of Dengue fever, and called on all people to clean up mosquito breeding sites.

23 Dec 2010

Bacterium used to tackle Dengue fever

This January Australian scientists will start deploying a strange bacterium called Wolbachia pipientis in an attempt to halt disease transmission by mosquitoes especially Dengue fever. They are targeting the Aedes aegypti mosquito that transmits Dengue. Dengue is a viral disease that leads to high fever, severe muscle and joint pain and can also be fatal.

9 Dec 2010

UIC scientist focuses on potential targets to inhibit malaria transmission

University of Illinois at Chicago researcher Dr. John Quigley will describe a promising new approach to blocking malaria transmission during the American Society of Hematology's annual meeting in Orlando, Fla.

6 Dec 2010

MicroRNA linked to mosquito blood digestion and egg development identified

Each year, dengue fever infects as many as 100 million people while yellow fever is responsible for about 30,000 deaths worldwide. Both diseases are spread by infected female Aedes aegypti mosquitoes, which require vertebrate blood to produce eggs. The blood feeding and the egg development are tightly linked to how the mosquito transmits the disease-causing virus.

2 Dec 2010

NIAID scientists confirm antiviral activity of two lead compounds against HPV

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds showed excellent in vitro antiviral activity and no cellular toxicity at dose levels tested for Human Papillomavirus (HPV).

30 Nov 2010

NPR reports on dengue vaccine progress

NPR's Shots blog examines progress in the search for a vaccine to protect against the dengue virus. WHO estimates that 2.5 billion people worldwide are at risk of getting dengue, and most of them are in Asia and Latin America, the blog writes.

16 Nov 2010

Inviragen to present data on CHIKV vaccine at ASTMH meeting

Inviragen, a biotechnology company developing vaccines to protect against infectious diseases worldwide, together with investigators at the University of Texas Medical Branch (UTMB) and the Division of Vector Borne Diseases (DVBD) of the Centers for Disease Control and Prevention, will make an oral presentation today at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting on preclinical results of the Company's experimental chikungunya virus (CHIKV) vaccine.

8 Nov 2010

Sanofi Pasteur's dengue vaccine enters phase III trial in Australia

Sanofi Pasteur, the vaccines division of the pharmaceutical group Sanofi-Aventis, on Thursday announced the company had begun testing its dengue fever vaccine in a Phase III clinical trial in Australia, Dow Jones/Wall Street Journal reports.

8 Nov 2010

Experts develop tools to educate people about health risks associated with global travel

More than 30 million people in the United States travel to resource-limited areas of the world each year. This global mobility may contribute to the spread of infectious diseases such as influenza, measles, and meningitis and may also put individual travelers at risk for malaria, typhoid, dengue fever and hepatitis.

4 Nov 2010

World's most clinically advanced dengue vaccine candidate enters first phase 3 clinical study

Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that its dengue vaccine is in final stage of clinical development. Sanofi Pasteur's dengue vaccine, the world's most clinically advanced dengue vaccine candidate, entered its first phase 3 clinical study in Australia.

4 Nov 2010